News - Copaxone, Pharmaceutical

Filter

Current filters:

CopaxonePharmaceutical

Popular Filters

Drug pricing power led by hepatitis C, diabetes and cancer

Drug pricing power led by hepatitis C, diabetes and cancer

13-06-2014

Hepatitis C, diabetes and cancer are sustaining high pricing power through innovation according to Morningstar's…

AbbVieAntibiotics and Infectious diseasesBiogen IdecCopaxoneDiabetesGenericsGilead SciencesMerck & CoOncologyPharmaceuticalPricingTecfideraTeva Pharmaceutical IndustriesUSA

US Supreme Court agrees to hear Teva’s Copaxone patent appeal

US Supreme Court agrees to hear Teva’s Copaxone patent appeal

01-04-2014

Israel’s Teva Pharmaceutical Industries, the world largest generic drugmaker, says that the US Supreme…

CopaxoneLegalNeurologicalNorth AmericaPatentsPharmaceuticalTeva Pharmaceutical IndustriesUSA

Teva receives subpoenas over Copaxone and Azilect marketing

Teva receives subpoenas over Copaxone and Azilect marketing

11-02-2014

The US Department of Justice is investigating Israel drugmaker Teva Pharmaceutical Industries’ marketing…

AzilectCopaxoneLegalMarkets & MarketingNeurologicalPharmaceuticalTeva Pharmaceutical Industries

Teva’s full year results steady led by Copaxone sales up 8%

Teva’s full year results steady led by Copaxone sales up 8%

07-02-2014

Israel-based Teva Pharmaceutical Industries has released its full year results for 2014 showing that…

CopaxoneEastern EuropeFinancialGenericsPharmaceuticalTeva Pharmaceutical Industries

Teva gets FDA approval of three-times-a-week Copaxone

Teva gets FDA approval of three-times-a-week Copaxone

29-01-2014

Israel’s Teva Pharmaceutical Industries says that the US Food and Drug Administration has approved…

CopaxoneNeurologicalNorth AmericaPharmaceuticalRegulationTeva Pharmaceutical IndustriesUSA

Teva provides 2014 financial outlook expecting big hit from Copaxone generics

Teva provides 2014 financial outlook expecting big hit from Copaxone generics

11-12-2013

Israel’s Teva Pharmaceutical Industries is itself bracing for competition from copies to its best-selling…

CopaxoneFinancialNeurologicalPharmaceuticalTeva Pharmaceutical Industries

FT Pharma 2013: Teva’s acting CEO says it has “a very strong and clear strategy”

FT Pharma 2013: Teva’s acting CEO says it has “a very strong and clear strategy”

05-12-2013

Eyal Desheh, acting president and chief executive of the world’s largest generics maker Teva (NYSE:…

CopaxoneGenericsInterviewsManagementPharmaceuticalRest of the WorldTeva Pharmaceutical Industries

Takeda to commercialize Teva’s glatiramer acetate for MS in Japan

Takeda to commercialize Teva’s glatiramer acetate for MS in Japan

05-12-2013

Revealing an earlier agreement yesterday, Israel’s Teva Pharmaceutical Industries and Japan’s largest…

Asia-PacificCopaxoneGlatiramer AcetateLicensingNeurologicalPharmaceuticalRegulationTakeda PharmaceuticalsTeva Pharmaceutical Industries

Teva unveils new pipeline assets from its 2013 NTE program

Teva unveils new pipeline assets from its 2013 NTE program

05-12-2013

Best known as the world’s biggest generic drugmaker, Israel’s Teva Pharmaceutical Industries yesterday…

Anti-viralsCopaxoneNeurologicalPharmaceuticalResearchTeva Pharmaceutical Industries

Teva denies claims its MS drug Copaxone profits set to slump

Teva denies claims its MS drug Copaxone profits set to slump

25-11-2013

Israel’s Teva Pharmaceutical Industries, the world’s largest generic drugmaker, this morning strongly…

CopaxoneEuropeFinancialMylan LaboratoriesNeurologicalPatentsPharmaceuticalTeva Pharmaceutical Industries

MS therapeutics market led by Copaxone

17-09-2013

The multiple sclerosis (MS) therapeutics market has been forecast to increase at a compound annual growth…

CopaxoneMarkets & MarketingNeurologicalPharmaceuticalTeva Pharmaceutical Industries

Teva Pharma sees slowdown in generic revenues

01-08-2013

Israel-based Teva Pharmaceutical Industries (NYSE: TEVA), the world largest generics firm but with a…

CopaxoneFinancialGenericsPharmaceuticalTeva Pharmaceutical Industries

US Appeals Court overturns Copaxone patent decision

28-07-2013

Israel-based generics giant Teva Pharmaceutical Industries ((NYSE: TEVA) said on Friday (July 26) that…

CopaxoneGenericsLegalMomenta PharmaceuticalsMylan LaboratoriesNatco PharmaNeurologicalNorth AmericaNovartisPatentsPharmaceuticalSandozTeva Pharmaceutical Industries

Teva fleshes out restructuring plan; licenses Xenon pain drug for $376 million

12-12-2012

Teva Pharmaceutical Industries (NYSE: TEVA's new chief executive Jeremy Levin has outlined the company's…

CopaxoneFinancialGenericsLicensingPatentsPharmaceuticalResearchTeva Pharmaceutical IndustriesXenon Pharmaceuticals

Teva gets favorable UK Copaxone patent ruling

12-07-2012

Israel-based Teva Pharmaceutical Industries (Nasdaq: TEVA) says that the UK High Court of Justice issued…

CopaxoneEuropeGenericsLegalMylan LaboratoriesNeurologicalPatentsPharmaceuticalTeva Pharmaceutical Industries

Teva prevails in Copaxone law suit with Mylan/Natco and Sandoz/Momenta

30-08-2011

Israel-headquartered Teva Pharmaceutical Industries (Nasdaq: TEVA) says that the US District Court for…

CopaxoneGenericsLegalMomenta PharmaceuticalsMylan LaboratoriesNatco PharmaNeurologicalNorth AmericaPatentsPharmaceuticalSandozTeva Pharmaceutical Industries

Back to top